/
/
Utilizzando RNA-sequenziamento per rilevare Novel Splice varianti correlati alla resistenza ai farmaci in<em> In Vitro</em> modelli di cancro
A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Department of Pediatric Oncology/Hematology,VU University Medical Center, 2Department of Hematology,VU University Medical Center, 3Department of Medical Oncology,VU University Medical Center, 4Department of Clinical Genetics,VU University Medical Center, 5Division of General and Transplant Surgery, Azienda Ospedaliera Universitaria Pisana,Universita’ di Pisa, 6Amsterdam Immunology and Rheumatology Center,VU University Medical Center, 7Princess Máxima Center for Pediatric Oncology, 8Cancer Pharmacology Lab, AIRC Start-Up Unit,University of Pisa, 9Institute of Nanoscience and Nanotechnology,CNR-Nano
Chapters
- 00:05Title
- 01:09Characterization of Drug Resistance Profiles through Cytotoxicity Assays
- 05:01RNA Isolation and Library Preparation for RNA-sequencing
- 05:55Validation of the Results by RT-PCR and qRT-PCR Assays
- 07:21Results: Detection of Differential Splicing Events in Chemotherapy-resistant Cell Lines Compared to Parental Wild-type by Using RNA-sequencing
- 09:07Conclusion
Qui si descrive un protocollo volto ad indagare l'impatto di aberrant splicing sulla resistenza ai farmaci nei tumori solidi e le neoplasie ematologiche. A questo scopo, abbiamo analizzato i profili trascrittomica dei modelli genitoriali e resistenti in vitro attraverso RNA-Seq e stabilito un metodo basato qRT-PCR per convalidare geni candidati.
